Pentoxifylline for rheumatoid arthritis inflammation
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests if pentoxifylline, a medicine typically used for circulation, can help reduce joint inflammation in people with rheumatoid arthritis who still have active symptoms despite taking standard DMARDs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active rheumatoid arthritis (RA) that is not in remission.
- You are between 18 and 70 years old.
- You are currently taking a conventional DMARD (like methotrexate) for your RA.
- You have not had bleeding in the eye or brain.
- You do not have serious kidney or liver disease, and you are not allergic to pentoxifylline.
- You are not pregnant or breastfeeding, and you are not taking a biologic or newer targeted DMARD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding roflumilast, a new medication, to your current rheumatoid arthritis treatment can help reduce joint inflammation and improve your symptoms. You would take it alongside methotrexate, a common RA medication you may already be using.
This study tests whether two drugs—roflumilast and desloratadine—added to your current rheumatoid arthritis medications can reduce joint inflammation and pain. You'd take these as add-ons to your existing treatment to see if they help control your disease better.
This trial tests whether increasing your methotrexate dose or switching from pills to injections can better control active rheumatoid arthritis. It's for people already taking a stable, moderate dose of methotrexate but still having joint swelling and symptoms.
This study tests whether combining two medicines—methotrexate and tofacitinib—works better for people with a specific type of rheumatoid arthritis. It may be a good fit if you have moderate to severe arthritis, have had a joint biopsy that shows a certain cell pattern, and haven't used similar treatments before.
This study tests if a new drug (Natrunix) combined with methotrexate can better control active rheumatoid arthritis in people whose RA is still active despite methotrexate alone.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.